Immunopathogenesis and therapy of cutaneous T cell lymphoma

被引:360
作者
Kim, EJ [1 ]
Hess, S
Richardson, SK
Newton, S
Showe, LC
Benoit, BM
Ubriani, R
Vittorio, CC
Junkins-Hopkins, JM
Wysocka, M
Rook, AH
机构
[1] Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA
[2] Wistar Inst Anat & Biol, Philadelphia, PA USA
关键词
D O I
10.1172/JCI200524826
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Cutaneous T cell lymphomas (CTCLs) are a heterogenous group of lymphoproliferative disorders caused by clonally derived, skin-invasive T cells. Mycosis fungoides (MF) and Sezary syndrome (SS) are the most common types of CTCLs and are characterized by malignant CD4(+)/CLA(+)/CCR4(+) T cells that also lack the usual T cell surface markers CD7 and/or CD26. As MF/SS advances, the clonal dominance of the malignant cells results in the expression of predominantly Th2 cytokines, progressive immune dysregulation in patients, and further tumor cell growth. This review summarizes recent insights into the pathogenesis and immunobiology of MF/SS and how these have shaped current therapeutic approaches, in particular the growing emphasis on enhancement of host antitumor immune responses as the key to successful therapy.
引用
收藏
页码:798 / 812
页数:15
相关论文
共 126 条
[21]   Imiquimod and resiquimod as novel immunomodulators [J].
Dockrell, DH ;
Kinghorn, GR .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (06) :751-755
[22]   Adenovirus-mediated intralesional interferon-γ gene transfer induces tumor regressions in cutaneous lymphomas [J].
Dummer, R ;
Hassel, JC ;
Fellenberg, F ;
Eichmüller, S ;
Maier, T ;
Slos, P ;
Acres, B ;
Bleuzen, P ;
Bataille, V ;
Squiban, P ;
Burg, G ;
Urosevic, M .
BLOOD, 2004, 104 (06) :1631-1638
[23]   Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides [J].
Dummer, R ;
Urosevic, M ;
Kempf, W ;
Kazakov, D ;
Burg, G .
DERMATOLOGY, 2003, 207 (01) :116-118
[24]   Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results [J].
Duvic, M ;
Hymes, K ;
Heald, P ;
Breneman, D ;
Martin, AG ;
Myskowski, P ;
Crowley, C ;
Yocum, RC .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (09) :2456-2471
[25]  
Edelson RL, 2001, ANN NY ACAD SCI, V941, P1
[26]   Cutaneous malignant melanoma in association with mycosis fungoides [J].
Evans, AV ;
Scarisbrick, JJ ;
Child, FJ ;
Acland, KM ;
Whittaker, SJ ;
Russell-Jones, R .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (05) :701-705
[27]   Increased CCR4 expression in cutaneous T cell lymphoma [J].
Ferenczi, K ;
Fuhlbrigge, RC ;
Pinkus, JL ;
Pinkus, GS ;
Kupper, TS .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2002, 119 (06) :1405-1410
[28]   The epidemiology of non-Hodgkin's lymphoma [J].
Fisher, SG ;
Fisher, RI .
ONCOGENE, 2004, 23 (38) :6524-6534
[29]   Retinoids synergize with interleukin-2 to augment IFN-γ and interleukin-12 production by human peripheral blood mononuclear cells [J].
Fox, FE ;
Kubin, M ;
Cassin, M ;
Niu, Z ;
Trinchieri, G ;
Cooper, KD ;
Rook, AH .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1999, 19 (04) :407-415
[30]   Impaired CD40L signaling is a cause of defective IL-12 and TNF-α production in Sezary syndrome:: circumvention by hexameric soluble CD40L [J].
French, LE ;
Huard, B ;
Wysocka, M ;
Shane, R ;
Contassot, E ;
Arrighi, JF ;
Piguet, V ;
Calderara, S ;
Rook, AH .
BLOOD, 2005, 105 (01) :219-225